OGEN ORAGENICS INC
Pharmaceutical Preparations · NYSE · SEC CIK 1174940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY11.8%
TTM EPS YoY-102.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-176.1%
ROA-120.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets66.7%
Debt / equity0.00x
Current ratio—
Interest coverage-547.81x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.58M | $1.18M | $645,470 | $670,543 | $930,894 | $449,679 | $341,542 | $1.67M |
| SG&A expense | $1.02M | $1.42M | $1.61M | $1.83M | $2.19M | $1.26M | $1.68M | $1.69M |
| Operating income | -$2.60M | -$2.59M | -$2.26M | -$2.50M | -$3.12M | -$1.71M | -$2.03M | -$3.36M |
| Interest expense | $6,555 | $414 | $3,727 | $7,454 | $7,039 | $572,310 | $199,127 | $10,969 |
| Pretax income | -$2.62M | -$2.58M | -$2.22M | -$2.42M | -$3.07M | -$2.27M | -$2.22M | -$3.35M |
| Income tax | -$20,526 | -$46,377 | -$22,625 | — | — | — | — | — |
| Net income | -$2.60M | -$2.53M | -$2.20M | -$2.29M | -$3.07M | -$2.27M | -$2.22M | -$3.35M |
| EPS (basic) | -0.58 | -0.57 | -0.51 | — | -1.96 | -3.10 | -3.65 | — |
| EPS (diluted) | -0.58 | -0.57 | -0.51 | — | -1.96 | -3.10 | -3.65 | — |
| Weighted avg. shares (diluted) | 4.51M | 4.43M | 4.30M | — | 1.56M | 731,817 | 607,208 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.23M | $3.86M | $6.11M | $4.40M | $11.40M | $1.97M | $3.42M | $864,840 |
| Short-term investments | — | — | — | $4.00M | — | — | — | — |
| Current assets | $3.28M | $5.49M | $7.49M | $10.07M | $12.71M | $2.14M | $3.87M | $1.47M |
| Total assets | $3.28M | $5.49M | $7.49M | $10.07M | $12.71M | $2.14M | $3.87M | $1.47M |
| Total liabilities | $2.19M | $1.82M | $1.31M | $1.79M | $2.87M | $4.27M | $3.73M | $1.68M |
| Shareholders' equity | $1.09M | $3.67M | $6.18M | $8.28M | $9.83M | -$2.13M | $137,688 | -$211,885 |
| Shares outstanding | 4.51M | 4.51M | 4.38M | 4.27M | 4.13M | 822,927 | 21.48M | 419,003 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.03M | -$2.19M | -$2.20M | -$2.84M | -$2.98M | -$1.31M | -$2.11M | -$2.02M |
| Investing cash flow | $0 | $0 | $4.00M | — | — | — | — | — |
| Financing cash flow | $396,589 | -$56,134 | -$92,004 | -$168,628 | $12.41M | -$132,963 | $4.67M | -$260,856 |
| Stock-based compensation | $25,116 | $17,583 | $17,386 | $611,839 | $6,040 | $6,779 | $17,706 | $57,683 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.